人工全膝关节置换术治疗膝关节伸直位强直畸形

目的探讨膝关节伸直位强直畸形患者行人工全膝关节置换术的手术要点和术后效果。方法1996年1月至2006年6月,对8例（9膝）膝关节伸直位强直畸形患者行人工全膝关节置换术。术前膝关节活动度均为0°,KSS膝关节评分平均为44分（10～68分）,功能评分平均为17分（-10～55分）。结果8例患者（9膝）围手术期出现的并发症包括髌腱止点撕脱1膝,髌骨下极部分撕脱骨折1膝,术后早期关节血肿1膝,皮肤浅表性感染1膝,经对症治疗后所有患者均治愈出院。术后平均随访40．4个月（7．0～120．0个月）,术后膝关节平均活动度89°（50°～120°）,术后KSS膝关节评分平均为81分（55～93分）,功能评分平均为79分（50～90分）。2例2膝分别存在5°和25°的伸展滞缺。1例1膝因为关节不稳于术后1年行翻修术,更换加厚的胫骨平台垫片。结论膝关节伸直位强直畸形患者行人工全膝关节置换术难度大,并发症发生率较高,但如能恰当处理,仍可以取得较满意的临床效果。术中膝关节的充分暴露,保留足够的髌骨床厚度,保护髌腱和膝关节的血液供应以及正确的软组织平衡技术是手术的关键。     

国产人工膝关节系统初步应用的经验总结

目的总结初步使用国产TC-Dynamic人工膝关节系统的临床效果和手术经验。方法本组使用国产TC—Dynamic人工膝关节行全膝关节置换术（TKA）40例60膝，术前膝关节外科学会评分（KSS）的膝评分平均为16．28分（-32～47分），功能评分平均为18．36分（-20～60分），膝关节活动度（ROM）平均为79．22°（20°～145°）。结果36例52膝术后获得平均随访时间为20．41m（1．5～40m），随访时KSS膝评分平均为84．88分（70～95分），功能评分平均为80．58分（55～90分），ROM平均为110．48°（85°～140°）。所有随访患者术后X线片均示下肢力线良好，假体位置满意，无透亮线及任何松动迹象。结论使用国产TC—Dynamic人工膝关节假体的TKA手术临床效果满意。手术操作简便，截骨量较少，如果手术配套器械的设计和制作工艺能够进一步改良和提高，则更利于临床应用。     

严重膝关节伸直挛缩的微创治疗

目的介绍一种治疗严重膝关节伸直挛缩的微创手术方法,探讨其临床疗效。方法1998年9月至2001年10月,共手术治疗22例膝关节伸直挛缩患者,手术包括小切口股四头肌成形术和关节镜清理术两部分。首先通过髌骨外上方的小切口行股四头肌成形术,逐步解除阻碍膝关节屈曲的关节内和关节外因素。在此基础上,再行关节镜下清理术。术后第1d即开始行功能锻炼。结果术后随访14￣63个月,平均42个月。22例患者中16例重度伸直挛缩患者行股四头肌肌腱延长术。膝关节屈曲由术前的平均27°(5°￣45°)增加到术后即刻的141°(120°￣150°);伸膝缺失由术前的平均0.9°(0°￣10°)减少到术后即刻的0.45°(0°￣5°)。随访结束时本组平均屈曲度为115°(75°￣150°),增加88°(45°￣125°),与术前相比差异有统计学意义(t=-19.317,P<0.01),平均伸膝缺失为1.1°(0°￣15°),增加0.2°。按照Judet标准,优16例,良5例,可1例。手术前后平均HSS膝关节功能评分分别为74分和94分。有1例患者切口发生浅表感染,另1例存在15°永久性伸膝缺失。结论该方法适用于大多数膝关节伸直型挛缩畸形,具有创伤小、并发症少、操作简单和疗效可靠等优点。它提供了一种全新的、能够替代传统方法的治疗手段。     

旋转铰链型人工膝关节临床应用近期疗效观察

目的探讨旋转铰链型人工膝关节临床应用的近期疗效。方法2002年7月～2005年4月，应用旋转铰链型人工膝关节假体进行全膝关节置换术治疗膝关节严重畸形和不稳定17例17膝。其中男8例，女9例；年龄41～79岁，平均59岁。左侧10例，右侧7例。患者均因膝关节疼痛人院，病程1～7年。其中骨性关节炎10例，类风湿性关节炎5例，左股骨骨折术后创伤性关节炎1例，左胫骨平台骨折术后创伤性关节炎合并前交叉韧带、内侧半月板损伤及内侧侧副韧带断裂1例。术前HSS（hospital for special surgery）评分36-58分，平均48．6分；术前膝关节屈曲活动度21～80°，平均57．4°。结果术后患者均获随访7个月～3年，平均23．6个月。无下肢静脉血栓形成或肺栓塞，无腓总神经麻痹、骨折或伸膝装置断裂等并发症发生。1例患者术后3个月出现迟发感染，再次手术取出假体，应用抗生素骨水泥间隔行膝关节旷置待二期置换。其余16例最后随访时，HSS评分78～98分，平均91．1分，较术前平均增加45．5分，且差异有统计学意义（P〈0．05）；术后2周，膝关节屈曲活动度为75～100°，平均85．2°，最后随访时膝关节屈曲活动度为85～123°，平均108．3°，与术前比较差异有统计学意义（P〈0．05）。结论旋转铰链型人工膝关节置换术近期疗效肯定，远期疗效尚待进一步随访。     

全膝关节置换术后严重异位骨化与关节僵硬

[目的]探讨全膝关节置换术后严重异位骨化与关节僵硬的关系。[方法]对420例接受全膝关节置换术的患者随访,其中9例出现了Ⅲ级异位骨化,分别测量并记录该9例患者术后2周、12个月的疼痛评分和膝关节活动度,拍摄X线片,测量异位骨的大小。随机抽取9例无异位骨化的关节置换术后患者作为对照组,并测量疼痛评分及活动度。分别将异位骨化组和对照组的结果进行对比。[结果]关节置换术后Ⅲ级异位骨化的发病率为2.1%,X线片显示异位骨>5 cm,侵及股四头肌,引起关节疼痛。异位骨化组术后2周疼痛评分平均25.6分,关节最大伸直角度平均1.1°,最大屈曲角度119.1°,与对照组比较差异均无统计学意义(P>0.05)。异位骨化组术后12个月疼痛评分平均15.56分,低于术后2周(P<0.01),与对照组术后12个月(25分)比较有显著差异(P<0.01)。关节活动度:伸直6.1°,屈曲91.7°与术后2周和对照组术后12个月比较均有显著差异(P<0.01)。[结论]全膝关节置换术后Ⅲ级异位骨化可以导致关节疼痛和活动度受限,是术后关节僵硬的原因之一,严重影响置换术后临床效果。     

股四头肌成形术并发症原因分析及其对策（附18例报告）

目的探讨股四头肌成形术并发症发生的原因及其处理方法.方法对206例股四头肌成形术进行回顾性分析,其中18例分别于术中或/和术后产生并发症,包括伸膝装置损伤、皮肤损害、伸膝无力、再次粘连和罕见的股骨后髁骨折,所有病例均予相应处理.结果平均随访4.7年,膝关节活动度最大120°～0°～5°,最小50°～3°,平均98.6°～0°～1.1°.结论发生并发症的原因为适应证选择欠妥、切口失当、操作粗暴、错误延长股直肌腱、粘连松解不彻底、术后引流不畅和功能锻炼失误;推荐应用股外侧切口、股直肌起点剥离、良好关闭关节囊和早期进行主被动功能锻炼.     

全膝关节置换术后粘连的关节镜松解术

目的介绍和评价以关节镜松解手术处理全膝关节置换术后因纤维粘连导致的关节僵硬的疗效.方法对5例平均年龄56岁(41～70岁)的全膝关节置换术后关节粘连病例施行了关节镜松解术.本组不包括伴有明显关节疼痛及因全膝关节置换术后感染而导致的关节活动受限病例.本组患者在膝关节置换手术中关节活动度测试正常.全膝关节置换术后3～12个月由于关节粘连入院施行关节松解,术前平均屈曲度为70°(60°～85°),2例分别有10°30°伸直受限.以3点标准入路进行关节镜检查,发现屈曲受限的主要原因是髌周和内外侧沟的粘连束带形成,镜下切除粘连束带被动活动膝关节,均获得良好的关节松解.对2例使用保留后十字韧带假体的伸直受限病例行后十字韧带松解.术后当天开始持续被动活动(CPM)锻炼.关节镜松解术后平均随访时间20个月(8～46个月).结果关节镜术后当时膝关节活动度平均116°(100°～130°),至最后随访时为105°(90°～115°).关节活动度平均提高35°.本组未出现并发症.结论与闭合手法松解和开放手术相比,关节镜松解术处理非疼痛性及非感染性,单纯因纤维粘连导致的膝关节僵硬是一项有效、可靠和安全的技术.为获得更好的效果,松解手术应在全膝关节置换术后3～6个月内施行.     

高屈曲度假体与全髁型假体早期临床疗效比较

目的 对比高屈曲度假体与传统全髁型假体全膝关节表面置换术后早期临床效果的差异。方法 选取2004年10月至2005年10月间50例（67个膝关节）接受全膝关节表面置换术的膝骨关节炎患者，随机分为A组（高屈曲度假体组，使用LPS—Flex假体）和B组（全髁型假体组／TTC组，使用PFC∑及GⅡ假体）。A组包括26例患者（32个膝关节），男5例，女21例，平均年龄（65．29±5．96）岁。B组包括24例患者（35个膝关节）。男4例，女20例，平均年龄（64．32±8．32）岁。平均随访时间为1年8个月（1～2年）。结果 术前HSS评分为A组（58．61±11．40）分，B组（55．73±13．42）分，两组间无显著差异；术前膝关节活动度为A组（92±12．6）。（-15°～110°），B组（95±11．8）。（-15°～115°），两组间无显著差异。术后末次随访时HSS评分为A组（91．42±6．1）分，B组（92．67±6．33）分，两组间无显著差异；膝关节活动度为A组（124．68±10．32）。（-5°～137°），B组（102．56±15．44）。（-5°～118°），两组间有显著差异，A组患者膝关节屈曲功能明显优于B组。术后并发症包括：A组1例双膝全膝关节置换患者术后3个月时右膝关节感染，1例患者术后深静脉血栓形成；B组1例单膝全膝关节置换患者术后2周伤口脂肪液化，2例患者术后发生深静脉血栓。结论 全膝关节置换术中使用高屈曲度假体与使用传统全髁型假体相比，在改善患者疼痛、恢复行走功能以及手术并发症率方面无显著差别，但术后所能达到的屈曲度有显著差异。     

后稳定型全膝关节假体置换术后疗效分析

目的　分析后稳定型全膝关节假体置换术的处理方式、手术经验及疗效。方法　对 14例15膝行关节置换 ,使用Apollo后稳定型假体 ,单膝关节置换 13例 ,双膝同期置换 1例。原发疾病为类风湿性关节炎 3例 4膝 ,骨关节炎 11例 11膝。术后随访时间平均 11个月。结果　 15个膝关节术前伸曲活动度平均 75°,全膝关节置换术后 2个月关节活动度恢复至平均 10 0°。 14例患者均可自如行走、上下楼梯 ,膝关节稳定性好。 1膝术后脂肪液化致表层伤口裂开 ,清创后愈合 ,余膝术后伤口均愈合良好。结论　后稳定型假体植入的全膝关节置换手术方式简单、疗效肯定、术后并发症少。     

人工全膝表面关节置换治疗骨性膝关节炎47例

目的　分析总结人工全膝表面关节置换治疗骨性膝关节炎的临床效果及经验。方法　对 4 7例 5 3膝的骨性膝关节炎病例行人工膝关节置换术 ,单膝关节置换 4 1例 ,双膝关节置换 6例 1 2膝。应用后方稳定型假体 2 1例 2 5个膝关节 ,保留后交叉韧带型假体 2 6例 2 8个膝关节。结果　 39例 4 5个膝关节获 1年以上随访 ,采用HSS评分标准 ,膝关节评分从术前 35分提高到术后 89分 ,术后 4 0个膝关节活动度≥ 90°,4 2 / 4 5膝关节术后膝关节力线正常 ,3例残留 5°～ 7°内翻。结论　人工全膝表面关节置换治疗骨性膝关节炎可取得良好效果。术中精确的截骨操作与正确的软组织松解获得的软组织平衡是手术治疗成功的关键。     

维生素D受体在糖尿病肾病足细胞损伤及蛋白尿缓解中的作用

目的探讨维生素D受体(VDR)在糖尿病肾病(DKD)足细胞中的表达水平及在足细胞损伤及蛋白尿缓解中的作用。方法(1)本研究纳入了65例诊断患有2型糖尿病(伴或不伴蛋白尿)的患者,并纳入了25例年龄和性别相匹配的健康体检者为对照组。根据白蛋白/肌酐(ACR)的尿排泄比例对2型糖尿病患者进行分组,分别为无蛋白尿(ACR<30 mg/g,n=24)、微量白蛋白尿(ACR 30~300 mg/g,n=18)和临床蛋白尿(ACR>300 mg/g,n=23)。另选择25例经肾活检确诊的DKD患者作为DKD组。正常肾脏组织标本均取自泌尿外科同一时期肾脏肿瘤切除患者10例。将各组检测指标进行对比,同时采用实时定量PCR、ELISA法和免疫组化法检测VDR在各组患者的血液、尿液样本和肾脏组织中的表达情况,以及使用Pearson相关分析分析VDR与尿蛋白的相关性。(2)在2型糖尿病肾病小鼠模型中对上述结果进行验证,将遗传背景均为C57BLKs/J的雄性db/db小鼠及同窝出生的db/m小鼠,随机分为正常对照组(A组)、DKD对照组(B组)、DKD二甲基亚砜处理组(C组)、DKD帕立骨化醇(VDR激动剂)处理组(D组),C、D组连续腹腔注射处理8周,对照组不做任何处理。小鼠10周龄时开始连续干预8周,在小鼠22周龄(开始干预后12周)检测各组小鼠体重、血、尿生化指标对比;Western印迹法检测β⁃catenin、VDR的变化;免疫荧光观察足细胞标志蛋白podocin及足细胞损伤蛋白α⁃SMA的表达变化。结果(1)与正常健康对照组相比,无蛋白尿组、微量白蛋白尿组和临床蛋白尿组的糖尿病患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05);与无蛋白尿组的糖尿病患者相比,微量白蛋白尿组和临床蛋白尿组的糖尿病患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05)。(2)与正常健康对照组相比,无蛋白尿糖尿病组和DKD组患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05);与无蛋白尿糖尿病组患者相比,DKD组患者血浆中VDR的mRNA和蛋白水平亦较低(均P<0.05)。(3)免疫组化结果显示,DKD组肾组织中VDR的表达明显少于正常对照组。(4)DKD患者血浆中VDR mRNA相对水平与ACR呈负相关(r=-0.342,P<0.05)。(5)各组尿液上清液中VDR的水平与血浆中的水平呈相反趋势。(6)Western印迹结果显示,B组、C组肾小球足细胞β⁃catenin蛋白表达高于D组(均P<0.05),VDR蛋白的表达低于D组(均P<0.05);免疫荧光结果显示,B组、C组肾小球足细胞podocin的表达低于D组(均P<0.05),α⁃SMA的表达高于D组(均P<0.05)。结论VDR高表达缓解DKD足细胞损伤及蛋白尿。     

Anterior Interosseous Nerve Palsy After Shoulder Arthroscopy Treated With Surgical Decompression: A Case Series and Systematic Review of the Literature

Background: Anterior interosseous nerve (AIN) palsy is a very uncommon cause of upper extremity pain and weakness that comprises less than 1% of all upper extremity nerve palsies. Rarely reported but also mentioned in the literature is AIN palsy after shoulder arthroscopy. Methods: A systematic review of the literature to date using PubMed was conducted to identify patients who suffered AIN palsy after shoulder arthroscopy procedures. Articles included met the following criteria: (1) published in English; (2) primary presentation of the data; (3) patients had undergone shoulder arthroscopy before developing symptoms of AIN palsy; and (4) diagnosis was confirmed with clinical symptoms of AIN palsy. Measured outcomes included patient demographics, specific shoulder procedure, anesthesia procedure, intra-operative patient positioning, intra-operative compressive dressing, intra-operative traction, surgical versus conservative treatment, abnormal findings during decompression procedure, proposed mechanism of injury, and follow-up. Results: The search yielded 6 articles, of which 4 (13 cases) met inclusion criteria. An additional 2 cases were included in this report totaling 15 cases. The average patient age was 49 years (range: 31-64) with 73% males. At average follow-up of 24 months, 67% of patients experienced complete resolution of symptoms—more than half of which underwent surgical decompression. Patients who failed to progress experienced weakness of the flexor digitorum profundus and flexor pollicis longus muscles. Conclusions: Proposed injury mechanisms for AIN palsy after shoulder arthroscopy range from mechanical trauma, compressive hematoma, and direct anesthetic neurotoxicity. Management should be directed by clinical symptoms, imaging, and patient factors with majority of patients expected to have excellent clinical outcomes.     

不同尿钙水平的Gitelman综合征患者临床特点比较

目的观察不同尿钙水平Gitelman综合征(GS)患者的临床特点,探讨尿钙在GS疾病临床分型中的价值。方法收集2016—2018年来自中国国家罕见病注册系统(NRSC)、在北京协和医院行SLC12A3基因检测诊断为GS患者的临床资料,分析其尿钙特点,比较不同尿钙水平患者的临床和实验室检查指标。氢氯噻嗪试验按照标准操作流程进行,测定患者基线和用药后3 h内氯离子排泄分数改变量的最大值(ΔFECl)。结果共有83例GS患者被纳入研究,其中低尿钙患者53例(63.86%)。低尿钙组尿钙/肌酐比明显低于非低尿钙组[(0.085±0.058)mmol/mmol比(0.471±0.284)mmol/mmol,t=7.349,P<0.001]。两组患者在年龄、性别、估算肾小球滤过率、血压、血尿电解质水平、代谢性碱中毒方面差异均无统计学意义。低尿钙组患者乏力(χ2=4.595,P=0.032)及多尿(χ2=5.778,P=0.016)发生比例低于非低尿钙组,两组患者在其他临床症状方面差异无统计学意义。低尿钙和非低尿钙组各有16例患者行氢氯噻嗪试验,中位ΔFECl结果分别为0.539%(0.430%,1.283%)和0.829%(0.119%,1.298%),均提示对氢氯噻嗪无反应,组间差异无统计学意义(U=130.000,P=0.956)。结论GS患者中低尿钙比例为63.86%,尿钙水平与疾病临床表型、NCC功能损伤严重程度之间均无明确相关性。     

Fibrinogen-thrombin collagen patch reinforcement of highrisk colonic anastomoses in rats

AIM To evaluate the effectiveness of human fibrinogenthrombin collagen patch(TachoSil~?) in the reinforcement of high-risk colon anastomoses.METHODS A quasi-experimental study was conducted in Wistar rats(n = 56) that all underwent high-risk anastomoses(anastomosis with only two sutures) after colectomies. The rats were divided into two randomized groups: Control group(24 rats) and treatment group(24 rats). In the treatment group, high-risk anastomosis was reinforced with TachoSil~? (a piece of Tacho Sil? was applied over this high-risk anastomosis, covering the gap). Leak incidence, overall survival, intra-abdominal adhesions, and histologic healing of anastomoses were analyzed. Survivors were divided into two subgroups and euthanized at 15 and 30 d after intervention in order to analyze the adhesions and histologic changes. RESULTS Overall survival was 71.4% and 57.14% in the TachoSil~? group and control group, respectively(P = 0.29); four rats died from other causes and six rats in the treatment group and 10 in the control group experienced colonic leakage(P 0.05). The intra-abdominal adhesion score was similar in both groups, with no differences between subgroups. We found non-significant differences in the healing process according to the histologic score used in both groups(P = 0.066).CONCLUSION In our study, the use of TachoSil~? was associated with a non-statistically significant reduction in the rate of leakage in high-risk anastomoses. TachoSil~? has been shown to be a safe product because it does not affect the histologic healing process or increase intra-abdominal adhesions.     

Role of Conventional and Diffusion-Weighted Magnetic Resonance Imaging of Spinal Treatment Protocol for Hydatid Disease

Objective:

To demonstrate the role of magnetic resonance imaging (MRI) in determining the treatment protocol for hydatid disease of the spine.

Design:

Case report; literature review.

Findings:

Diffusion-weighted MRI can help differentiate complicated infected hydatidosis from abscesses, epidermoid cysts from arachnoid cysts, and benign from malignant vertebral compression fractures. It is also helpful in differentiating between abscesses and necrotic tumors.

Conclusion:

Diffusion-weighted MRI can help differentiate between infections requiring immediate surgery and those that can be treated medically with antihelmintic treatment.     

Fluorescence in the Sclera,Nails, and Teeth Secondary to Favipiravir Use for COVID-19 Infections

Favipiravir, an antiviral agent originally used for influenza infections, has become popular due to its beneficial signals in coronavirus disease. It is currently used in some countries within COVID-19 treatment protocols. This is an initial report of favipiravir-related fluorescence observed in three healthcare providers working in the same ward in our hospital. All three individuals had been diagnosed with COVID-19 two months earlier and were treated with favipiravir. None of the three individuals received hydroxychloroquine or tetracyclines. Wood’s light examination led to an incidental discovery of favipiravir-induced fluorescence involving the sclera, nails, and teeth. In all patients, white linear, square, and band-like specks of fluorescence were noticed on the sclera of both eyes, some teeth, and the proximal part of all fingernails and toenails. Exposure of the eyes to the Wood’s light was for a brief duration of 3 to 5 seconds during examination and photodocumentation. Favipiravir might cause bright white fluorescence of nails, sclera, and teeth, detectable by Wood’s light even two months after its cessation.     

Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers

BACKGROUND: Sugammadex rapidly reverses rocuronium- and vecuronium-induced neuromuscular block. To investigate the effect of combination of sugammadex and rocuronium or vecuronium on QT interval, it would be preferable to avoid the interference of anaesthesia. Therefore, this pilot study was performed to investigate the safety, tolerability, and plasma pharmacokinetics of single i.v. doses of sugammadex administered simultaneously with rocuronium or vecuronium to anaesthetized and non-anaesthetized healthy volunteers. METHODS: In this phase I study, 12 subjects were anaesthetized with propofol/remifentanil and received sugammadex 16, 20, or 32 mg kg(-1) combined with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1); four subjects were not anaesthetized and received sugammadex 32 mg kg(-1) with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1) (n=2 per treatment). Neuromuscular function was assessed by TOF-Watch SX monitoring in anaesthetized subjects and by clinical tests in non-anaesthetized volunteers. Sugammadex, rocuronium, and vecuronium plasma concentrations were measured at several time points. RESULTS: No serious adverse events (AEs) were reported. Fourteen subjects reported 23 AEs after study drug administration. Episodes of mild headache, tiredness, cold feeling (application site), dry mouth, oral discomfort, nausea, increased aspartate aminotransferase and gamma-glutamyltransferase levels, and moderate injection site irritation were considered as possibly related to the study drug. The ECG and vital signs showed no clinically relevant changes. Rocuronium/vecuronium plasma concentrations declined faster than those of sugammadex. CONCLUSIONS: Single-dose administration of sugammadex 16, 20, or 32 mg kg(-1) in combination with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1) was well tolerated with no clinical evidence of residual neuromuscular block, confirming that these combinations can safely be administered simultaneously to non-anaesthetized subjects. Rocuronium and vecuronium plasma concentrations decreased faster than those of sugammadex, reducing the theoretical risk of neuromuscular block developing over time.     

血浆凝血因子VIII水平与IgA肾病患者临床病理改变及预后的关系

目的探讨血浆凝血因子VIII(factor VIII,FVIII)水平与IgA肾病(IgAN)患者临床参数及预后的关系。方法收集2016年1月至2016年12月中南大学湘雅二医院确诊的IgAN患者的临床资料。按照时间依赖的受试者工作特征曲线(ROC)得出的血浆FVIII预测IgAN预后的临界值,将患者分为高FVIII组(FVIII>140.50%)和低FVIII组(FVIII≤140.50%),比较两组患者肾活检时基线临床参数的差异。以估算肾小球滤过率(eGFR)下降≥30%或进入终末期肾脏病(ESRD)为终点事件,采用Kaplan-Meier生存曲线及Cox回归方程法分析血浆FVIII水平对IgAN患者预后的影响。结果共93例IgAN患者纳入本研究,中位随访时间为35.15(33.77,36.76)个月,12例(12.90%)患者发生终点事件。高FVIII组患者年龄、血肌酐、尿素氮、血三酰甘油、血总胆固醇、血浆纤维蛋白原、D-二聚体、24 h尿蛋白量、蛋白C、蛋白S和eGFR下降速率高于低FVIII组(均P<0.05);eGFR、血白蛋白、中位随访时间低于低FVIII组(均P<0.05)。Kaplan-Meier生存分析结果显示,与低FVIII组比较,高FVIII组患者肾脏累积生存率降低(χ2=5.635,P=0.018)。在校正收缩压、eGFR、尿蛋白、肾小管萎缩/间质纤维化程度等因素后,多因素Cox回归分析结果显示,高血浆FVIII水平是IgAN患者肾脏预后不良的独立危险因素(HR=4.147,95%CI 1.055~16.308,P=0.042)。结论血浆FVIII水平与IgAN患者临床指标及预后相关,高血浆FVIII水平是IgAN患者肾脏预后不良的独立危险因素。     

罗伊适应模式对腹股沟疝无张力疝修补术后恢复情况的影响

目的探讨罗伊适应模式对患者腹股沟疝无张力疝修补术后恢复情况的影响。 方法将2016年1月至2019年5月在秦皇岛市第二医院择期进行无张力修补术治疗的120例腹股沟疝患者，按照随机数字法分为对照组和观察组，每组各60例。对照组采用常规护理治疗，观察组在对照组的基础上采用罗伊适应模式。比较2组患者的术后临床指标、心理状态、围手术期并发症发生情况及满意度。 结果术后观察组患者的首次排气时间、恢复正常饮食时间、离床活动时间和术后住院时间均低于对照组（P<0.05）；术后观察组患者的抑郁自评量表（SDS）和焦虑自评量表（SAS）评分显著低于对照组（P<0.05）；术后2组患者均无切口感染发生，2组患者尿潴留、急性疼痛、认知功能障碍、发热、血肿等发生率相比无统计学差异（P>0.05）；术后观察组患者护理满意度为96.67%，显著高于对照组的83.33%（P<0.05）。 结论在常规护理的基础上，罗伊适应模式用于患者腹股沟疝无张力修补围手术期，能有效改善术后患者的焦虑/抑郁情绪，不增加围手术期并发症，促进术后患者的恢复及提高治疗满意度。     

Factors Associated With Reoperation After Silicone Proximal Interphalangeal Joint Arthroplasty

Background: Silicone proximal interphalangeal (PIP) joint arthroplasty has a high revision rate. It has been suggested that persistent ulnar deviation and joint instability influence the durability of PIP silicone arthroplasties. The goal of this study was to evaluate what factors are associated with reoperation after silicone PIP arthroplasty. Methods: We retrospectively evaluated all adult patients who underwent PIP silicone arthroplasty between 2002 and 2016 at one institutional system for inflammatory-, posttraumatic-, and primary degenerative arthritis. After manual chart review, we included 91 patients who underwent 114 arthroplasties. Fingers operated included 14 index, 41 middle, 38 ring, and 21 small fingers. Results: The overall reoperation rate was 14% (n = 16). Non-Caucasian race (P = .040), smoking (P = .022) and PIP silicone arthroplasty for post-traumatic osteoarthritis (P = .021) were associated with reoperation. The 1-, 5- and 10-year implant survival rates were 87%, 85%, and 85%, respectively. Conclusion: Caution should be exercised when considering PIP silicone arthroplasty of the index finger or in patients with post-traumatic osteoarthritis. It may be worthwhile addressing smoking behavior before pursuing silicone PIP arthroplasty.